Synergistic antiplatelet action of nitric oxide (NO) with PGD2 and its metabolite PGJ2--relevance for cerebral circulation?
The PGI2/NO axis is well accepted for its central regulatory role in maintaining haemostatic balance in large arteries. Earlier findings suggest that PGD2 may also play a role in haemostatic regulation of human cerebral circulation. We therefore wondered whether PGD2 and its metabolite PGJ2 synergise in-vitro with NO. We approached this question using platelets of ten healthy donors and ADP as aggregation-inducing stimulus. Both PGD2 and PGJ2 do inhibit ADP-induced platelet aggregation in a dose-dependent manner. Platelet aggregation findings demonstrate that PGD2 and NO synergise, as does the metabolite PGJ2. Our data are indicative that the PGD2/NO and, in less extent, PGJ2/NO synergism might be of special importance for the cerebrovascular haemostatic control.
Rodrigues
M
M
Department of Nuclear Medicine, University of Vienna, Austria.
Fitscha
P
P
Sinzinger
H
H
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004357:Drug Synergism; D011464:Epoprostenol / Q000494:pharmacology; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009569:Nitric Oxide / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D015230:Prostaglandin D2 / Q000031:analogs & derivatives* / Q000494:pharmacology
D000970:Antineoplastic Agents; D010975:Platelet Aggregation Inhibitors; D009569:Nitric Oxide; C037112:9-deoxy-delta-9-prostaglandin D2; D000244:Adenosine Diphosphate; D011464:Epoprostenol; D015230:Prostaglandin D2